Sanofi Pasteur MSD Welcomes the Publication of a Special Issue on the Economic Value of Vaccination

LYON, France, September 17, 2015 /PRNewswire/ --

A relevant and comprehensive approach on the benefits of vaccines on healthcare

systems sustainability and economic growth  

Sanofi Pasteur MSD is proud to announce the publication of a supplement dedicated to the economic value of vaccination in the Journal of Market Access and Health Policy. The series of 7 articles has been developed by Sanofi Pasteur MSD and a group of 11 public health and economics experts, from 8 EU countries.

To view the Multimedia News Release, please click:

"Prevention is one of the most appropriate responses to Europe's health and growth challenges" said Andrea Rappagliosi, Vice President Market Access, Health Policy and Medical Affairs of Sanofi Pasteur MSD. "Vaccination helps tackle resurging and emerging infectious diseases and improve the health of an ageing population. This publication provides further evidence of Sanofi Pasteur MSD's leading position in Europe as a health partner of choice," he concluded.

Vaccination represents today only 0.3% of healthcare expenditure in an EU country like France. Although a minor fraction of the healthcare budget is allocated to vaccination programs in Europe, these have a central role in prevention policies and are recognized as one of the most cost-effective public health interventions. Beyond acknowledged impact on public health, this series of articles depicts impact of vaccination on economic growth, sustainability and efficiency of healthcare systems. It emphasizes several invisible gains from vaccination that are traditionally ignored in economic analyses.

"This series of articles constitutes a comprehensive source of information on vaccination' benefits and depicts the problem from different angles and perspectives. They help to realize the broad spectrum of benefits that add to health, economic and societal gains of immunization" said Prof. Mondher Toumi and Prof. Walter Ricciardi. "Bringing this message to the patients and authorities and increasing awareness of true value of vaccination is of great importance nowadays. Promoting and strengthening the role of vaccines is in line with recently published document by Council of the European Union," they added.

Exclusively dedicated to vaccines in Europe, Sanofi Pasteur MSD is a committed public health partner, fully focused on Europe's future, people and healthcare systems. This approach aims to demonstrate that vaccines have relevance for wider economic planning and require adequate value recognition to ensure quick population access and wide acceptability.


Sanofi Pasteur MSD

CONTACT: ContactSanofi Pasteur MSDSylvia Martin-JarrandTel : +33-4-37-28-40-55smartin-jarrand@spmsd.comSanofi Pasteur MSDLoïc

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234